{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T10:30:22Z","timestamp":1793961022511,"version":"4.8.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.eprac.2026.06.016","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T12:53:05Z","timestamp":1783601585000},"page":"1734-1740","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Normocalcemic Primary Hyperparathyroidism: An Evolving Understanding"],"prefix":"10.1016","volume":"32","author":[{"given":"Salina A.","family":"Kalik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ejigayehu G.","family":"Abate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3042-5336","authenticated-orcid":false,"given":"Natalie E.","family":"Cusano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.eprac.2026.06.016_bib1","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1210\/jc.2014-1415","article-title":"Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop","volume":"99","author":"Silverberg","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eprac.2026.06.016_bib2","doi-asserted-by":"crossref","first-page":"R33","DOI":"10.1530\/EJE-21-1044","article-title":"European expert consensus on practical management of specific aspects of parathyroid disorders in adults and in pregnancy: recommendations of the ESE Educational Program of Parathyroid Disorders (PARAT 2021)","volume":"186","author":"Bollerslev","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.eprac.2026.06.016_bib3","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1210\/jc.2008-1760","article-title":"Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop","volume":"94","author":"Silverberg","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.eprac.2026.06.016_bib4","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/jbmr.4677","article-title":"Evaluation and Management of Primary Hyperparathyroidism: summary statement and guidelines from the fifth international workshop","volume":"37","author":"Bilezikian","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"7","key":"10.1016\/j.eprac.2026.06.016_bib5","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa174","article-title":"Clinical, biochemical, and radiological profile of normocalcemic primary hyperparathyroidism","volume":"105","author":"Palermo","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.eprac.2026.06.016_bib6","doi-asserted-by":"crossref","first-page":"e1171","DOI":"10.1210\/clinem\/dgaa084","article-title":"Normocalcemic hyperparathyroidism: study of its prevalence and natural history","volume":"105","author":"Schini","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2026.06.016_bib7","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/imj.15502","article-title":"Normocalcaemic primary hyperparathyroidism: is nephrolithiasis more common than osteoporosis?","volume":"53","author":"Wu","year":"2023","journal-title":"Intern Med J"},{"issue":"3","key":"10.1016\/j.eprac.2026.06.016_bib8","doi-asserted-by":"crossref","first-page":"e868","DOI":"10.1210\/clinem\/dgae659","article-title":"Approach to the patient: normocalcemic primary hyperparathyroidism","volume":"110","author":"Liu","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.eprac.2026.06.016_bib9","doi-asserted-by":"crossref","first-page":"666","DOI":"10.20945\/2359-3997000000556","article-title":"Normocalcemic primary hyperparathyroidism","volume":"66","author":"Cusano","year":"2022","journal-title":"Arch Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.eprac.2026.06.016_bib10","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1055\/a-0859-1020","article-title":"Normocalcemic primary hyperparathyroidism in adults without a history of nephrolithiasis or fractures: a prospective study","volume":"51","author":"Ros\u00e1rio","year":"2019","journal-title":"Horm Metab Res"},{"issue":"3","key":"10.1016\/j.eprac.2026.06.016_bib11","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1530\/EC-15-0030","article-title":"Normocalcemic primary hyperparathyroidism: a survey in a small village of Southern Italy","volume":"4","author":"Vignali","year":"2015","journal-title":"Endocr Connect"},{"issue":"7","key":"10.1016\/j.eprac.2026.06.016_bib12","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1210\/jc.2013-1300","article-title":"Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations","volume":"98","author":"Cusano","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2026.06.016_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjsurg.2025.116272","article-title":"Patients with normocalcemic versus hypercalcemic hyperparathyroidism: what's really the difference?","volume":"244","author":"Balachandra","year":"2025","journal-title":"Am J Surg"},{"key":"10.1016\/j.eprac.2026.06.016_bib14","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1515\/cclm-2026-0545","article-title":"Albumin-adjusted (\u201ccorrected\u201d) calcium should no longer be reported: a position statement from the Joint IOF Working Group and IFCC Committee on Bone Metabolism and EFLM Committee on CKD","volume":"64","author":"Cavalier","year":"2026","journal-title":"Clin Chem Lab Med"},{"issue":"9","key":"10.1016\/j.eprac.2026.06.016_bib15","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1210\/jc.2012-1429","article-title":"The importance of measuring ionized calcium in characterizing calcium status and diagnosing primary hyperparathyroidism","volume":"97","author":"Ong","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"10-11","key":"10.1016\/j.eprac.2026.06.016_bib16","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.clinbiochem.2011.04.002","article-title":"Biochemical diagnosis of primary hyperparathyroidism: analysis of the sensitivity of total and ionized calcium in combination with PTH","volume":"44","author":"Nordenstr\u00f6m","year":"2011","journal-title":"Clin Biochem"},{"key":"10.1016\/j.eprac.2026.06.016_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2022.965376","article-title":"Prevalence, trend, and predictor analyses of vitamin D deficiency in the US population, 2001-2018","volume":"9","author":"Cui","year":"2022","journal-title":"Front Nutr"},{"issue":"14","key":"10.1016\/j.eprac.2026.06.016_bib18","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1001\/jama.2021.3069","article-title":"Screening for vitamin D deficiency in adults: US preventive services task force recommendation statement","volume":"325","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.eprac.2026.06.016_bib19","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00774-005-0647-y","article-title":"Causes of secondary hyperparathyroidism in a healthy population: the Troms\u00f8 study","volume":"24","author":"Saleh","year":"2006","journal-title":"J Bone Miner Metab"},{"issue":"10","key":"10.1016\/j.eprac.2026.06.016_bib20","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/BF03346429","article-title":"Role of calcium malabsorption in the development of secondary hyperparathyroidism after biliopancreatic diversion","volume":"31","author":"Balsa","year":"2008","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"10.1016\/j.eprac.2026.06.016_bib21","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jacc.2020.09.617","article-title":"Vitamin D, calcium supplements, and implications for cardiovascular health: JACC focus seminar","volume":"77","author":"Michos","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.eprac.2026.06.016_bib22","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1210\/jc.2010-2704","article-title":"The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know","volume":"96","author":"Ross","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.eprac.2026.06.016_bib23","first-page":"O1","volume":"28","author":"Mechanick","year":"2020","journal-title":"Obes Med Assoc Am Soc Anesthesiologists Obes (Silver Spring)"},{"issue":"10","key":"10.1016\/j.eprac.2026.06.016_bib24","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.eprac.2022.07.009","article-title":"Calcium challenge to confirm secondary hyperparathyroidism caused by decreased calcium intake","volume":"28","author":"Shokry","year":"2022","journal-title":"Endocr Pract"},{"key":"10.1016\/j.eprac.2026.06.016_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2023.1177829","article-title":"Pathophysiology of bone disease in chronic kidney disease: from basics to renal osteodystrophy and osteoporosis","volume":"14","author":"Aguilar","year":"2023","journal-title":"Front Physiol"},{"issue":"1","key":"10.1016\/j.eprac.2026.06.016_bib26","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1053\/j.ajkd.2022.06.006","article-title":"Vitamin D and parathyroid hormone levels in CKD","volume":"81","author":"Dhillon-Jhattu","year":"2023","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.eprac.2026.06.016_bib27","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1186\/s12882-017-0755-7","article-title":"Changes in urinary risk profile after short-term low sodium and low calcium diet in recurrent Swiss kidney stone formers","volume":"18","author":"Seeger","year":"2017","journal-title":"BMC Nephrol"},{"issue":"2","key":"10.1016\/j.eprac.2026.06.016_bib28","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0002-9343(99)80134-X","article-title":"Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling","volume":"99","author":"Chesnut","year":"1995","journal-title":"Am J Med"},{"issue":"12","key":"10.1016\/j.eprac.2026.06.016_bib29","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.medcli.2024.07.020","article-title":"Hyperparathyroidism in patients with low bone mineral density treated with zoledronic acid or denosumab","volume":"163","author":"Riesco-B\u00e1rcena","year":"2024","journal-title":"Med Clin (Barc)"},{"issue":"10","key":"10.1016\/j.eprac.2026.06.016_bib30","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1111\/bcp.13332","article-title":"Effect of a single intravenous zoledronic acid administration on biomarkers of acute kidney injury (AKI) in patients with osteoporosis: a pilot study","volume":"83","author":"Cipriani","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.eprac.2026.06.016_bib31","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"Mcclung","year":"2006","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.eprac.2026.06.016_bib32","first-page":"2844","article-title":"Alterations in parathyroid dynamics in lithium-treated subjects","volume":"82","author":"Haden","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.eprac.2026.06.016_bib33","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.ecl.2021.08.001","article-title":"Drug-related hypercalcemia","volume":"50","author":"Lecoq","year":"2021","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"4 Pt 1","key":"10.1016\/j.eprac.2026.06.016_bib34","doi-asserted-by":"crossref","first-page":"C869","DOI":"10.1152\/ajpcell.1994.267.4.C869","article-title":"The Na-K-Cl cotransporters","volume":"267","author":"Haas","year":"1994","journal-title":"Am J Physiol"},{"issue":"6","key":"10.1016\/j.eprac.2026.06.016_bib35","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.2779","article-title":"Parathyroid hormone and the use of diuretics and calcium-channel blockers: the multi-ethnic study of atherosclerosis","volume":"31","author":"Zaheer","year":"2016","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.eprac.2026.06.016_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2024.117108","article-title":"Secondary hyperparathyroidism: predictors and relationship with vitamin D status, bone turnover markers and bone mineral density","volume":"184","author":"Fitzpatrick","year":"2024","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.eprac.2026.06.016_bib37","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1038\/s41467-019-12399-9","article-title":"Phosphate acts directly on the calcium-sensing receptor to stimulate parathyroid hormone secretion","volume":"10","author":"Centeno","year":"2019","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.eprac.2026.06.016_bib38","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1210\/jc.2002-021404","article-title":"Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone","volume":"88","author":"Maruani","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"7749","key":"10.1016\/j.eprac.2026.06.016_bib39","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0140-6736(72)90173-0","article-title":"Treatment with \u0153strogens of primary hyperparathyroidism in post-menopausal women","volume":"299","author":"Gallagher","year":"1972","journal-title":"The Lancet"},{"issue":"1","key":"10.1016\/j.eprac.2026.06.016_bib40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jocd.2012.12.001","article-title":"Normocalcemic primary hyperparathyroidism","volume":"16","author":"Cusano","year":"2013","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.eprac.2026.06.016_bib41","article-title":"Normocalcemic primary hyperparathyroidism is an early stage of primary hyperparathyroidism according to fibroblast growth factor 23 level","volume":"14","author":"Chertok","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"10.1016\/j.eprac.2026.06.016_bib42","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1007\/s12020-023-03476-7","article-title":"Genetic aspects underlying the normocalcemic and hypercalcemic phenotypes of primary hyperparathyroidism","volume":"82","author":"Viviani","year":"2023","journal-title":"Endocrine"},{"issue":"6","key":"10.1016\/j.eprac.2026.06.016_bib43","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/cen.14667","article-title":"Normocalcemic primary hyperparathyroidism: 99mTc SestaMibi SPECT\/CT results compare with hypercalcemic hyperparathyroidism","volume":"96","author":"Musumeci","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"10.1016\/j.eprac.2026.06.016_bib44","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1245\/s10434-018-6998-0","article-title":"Biochemical and skeletal outcomes of parathyroidectomy for Normocalcemic (Incipient) primary hyperparathyroidism","volume":"26","author":"Sho","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.eprac.2026.06.016_bib45","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40618-018-0931-z","article-title":"PETC\/CT with (18)F-Choline localizes hyperfunctioning parathyroid adenomas equally well in normocalcemic hyperparathyroidism as in overt hyperparathyroidism","volume":"42","author":"Bossert","year":"2019","journal-title":"J Endocrinol Invest"},{"issue":"8","key":"10.1016\/j.eprac.2026.06.016_bib46","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1210\/jc.2006-2802","article-title":"Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype","volume":"92","author":"Lowe","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.eprac.2026.06.016_bib47","doi-asserted-by":"crossref","first-page":"294","DOI":"10.4158\/EP15704.OR","article-title":"Primary hyperparathyroidism, with A focus on management of the normocalcemic form: to treat or not to treat?","volume":"22","author":"\u0160iprov\u00e1","year":"2016","journal-title":"Endocr Pract"},{"key":"10.1016\/j.eprac.2026.06.016_bib48","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1055\/a-2812-1864","article-title":"The fate of normocalcemic hyperparathyroidism: insights from a 3-Year multicenter Follow-Up","volume":"58","author":"Tuna","year":"2026","journal-title":"Horm Metab Res"},{"issue":"3","key":"10.1016\/j.eprac.2026.06.016_bib49","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00774-015-0673-3","article-title":"Normocalcemic hyperparathyroidism is associated with complications similar to those of hypercalcemic hyperparathyroidism","volume":"34","author":"Tuna","year":"2016","journal-title":"J Bone Miner Metab"},{"issue":"21","key":"10.1016\/j.eprac.2026.06.016_bib50","doi-asserted-by":"crossref","first-page":"6325","DOI":"10.3390\/jcm13216325","article-title":"Osteoporosis and normocalcemic primary hyperparathyroidism (conservatively or surgically managed)","volume":"13","author":"Gheorghe","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.eprac.2026.06.016_bib51","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/128352","article-title":"Normocalcemic versus hypercalcemic primary hyperparathyroidism: more stone than bone?","volume":"2012","author":"Amaral","year":"2012","journal-title":"J Osteoporos"},{"issue":"5","key":"10.1016\/j.eprac.2026.06.016_bib52","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00198-023-06669-y","article-title":"DXA-based bone strain index in normocalcemic primary hyperparathyroidism","volume":"34","author":"Tabacco","year":"2023","journal-title":"Osteoporos Int"},{"issue":"3","key":"10.1016\/j.eprac.2026.06.016_bib53","first-page":"163","article-title":"Clinical expression of calcium sensing receptor polymorphism (A986S) in normocalcemic and asymptomatic hyperparathyroidism","volume":"48","author":"D\u00edaz-Soto","year":"2016","journal-title":"Horm Metab Res"},{"issue":"10","key":"10.1016\/j.eprac.2026.06.016_bib54","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.eprac.2021.04.884","article-title":"Bone quality as measured by trabecular bone Score in normocalcemic primary hyperparathyroidism","volume":"27","author":"Naciu","year":"2021","journal-title":"Endocr Pract"},{"issue":"1","key":"10.1016\/j.eprac.2026.06.016_bib55","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.amjsurg.2019.10.032","article-title":"Comparative prospective study on the presentation of normocalcemic primary hyperparathyroidism. Is it more aggressive than the hypercalcemic form?","volume":"219","author":"G\u00f3mez-Ram\u00edrez","year":"2020","journal-title":"Am J Surg"},{"issue":"1","key":"10.1016\/j.eprac.2026.06.016_bib56","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s12020-024-03768-6","article-title":"Biochemical characteristics and clinical manifestation of normocalcemic primary hyperparathyroidism","volume":"85","author":"Yankova","year":"2024","journal-title":"Endocrine"},{"key":"10.1016\/j.eprac.2026.06.016_bib57","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/4558236","article-title":"Occult renal calcifications in patients with normocalcemic primary hyperparathyroidism and their association with the parathyroid hormone-vitamin D axis","volume":"2022","author":"Victor","year":"2022","journal-title":"Int J Endocrinol"},{"issue":"10","key":"10.1016\/j.eprac.2026.06.016_bib58","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1210\/clinem\/dgae162","article-title":"Comparison of normocalcemic vs hypercalcemic primary hyperparathyroidism in a hypercalciuric renal stone population","volume":"109","author":"Halimi","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2026.06.016_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115583","article-title":"Impaired physical function and evaluation of quality of life in normocalcemic and hypercalcemic primary hyperparathyroidism","volume":"141","author":"Voss","year":"2020","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.eprac.2026.06.016_bib60","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/0194599820983728","article-title":"Normocalcemic and normohormonal primary hyperparathyroidism: laboratory values and end-organ effects","volume":"165","author":"Hollowoa","year":"2021","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"5","key":"10.1016\/j.eprac.2026.06.016_bib61","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1530\/EJE-09-1067","article-title":"Cardiovascular risk factors and arterial rigidity are similar in asymptomatic normocalcemic and hypercalcemic primary hyperparathyroidism","volume":"162","author":"Tordjman","year":"2010","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2026.06.016_bib62","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1530\/eje.1.02173","article-title":"Metabolic abnormalities in patients with normocalcemic hyperparathyroidism detected at a population-based screening","volume":"155","author":"Hagstr\u00f6m","year":"2006","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.eprac.2026.06.016_bib63","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s00198-014-3000-2","article-title":"Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism","volume":"26","author":"Cesareo","year":"2015","journal-title":"Osteoporos Int"},{"issue":"5","key":"10.1016\/j.eprac.2026.06.016_bib64","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/PL00004171","article-title":"Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group","volume":"9","author":"Pols","year":"1999","journal-title":"Osteoporos Int"},{"issue":"1","key":"10.1016\/j.eprac.2026.06.016_bib65","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4081\/aiua.2015.1.66","article-title":"Use of cinacalcet in nephrolithiasis associated with normocalcemic or hypercalcemic primary hyperparathyroidism: results of a prospective randomized pilot study","volume":"87","author":"Brardi","year":"2015","journal-title":"Arch Ital Urol Androl"},{"issue":"5","key":"10.1016\/j.eprac.2026.06.016_bib66","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S2213-8587(20)30063-2","article-title":"Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Leere","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"10.1016\/j.eprac.2026.06.016_bib67","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1001\/jamasurg.2016.2310","article-title":"The American Association of Endocrine Surgeons guidelines for definitive management of primary hyperparathyroidism","volume":"151","author":"Wilhelm","year":"2016","journal-title":"JAMA Surg"},{"key":"10.1016\/j.eprac.2026.06.016_bib68","doi-asserted-by":"crossref","DOI":"10.1111\/1754-9485.12728","article-title":"Better performance of four-dimension computed tomography as a localization procedure in normocalcemic primary hyperparathyroidism","author":"Cunha-Bezerra","year":"2018","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"4","key":"10.1016\/j.eprac.2026.06.016_bib69","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1177\/0194599818793879","article-title":"Surgical management of normocalcemic primary hyperparathyroidism and the impact of intraoperative parathyroid hormone testing on outcome","volume":"159","author":"Trinh","year":"2018","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"2","key":"10.1016\/j.eprac.2026.06.016_bib70","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s00268-019-05157-x","article-title":"Biochemical profile affects IOPTH kinetics and cure rate in primary hyperparathyroidism","volume":"44","author":"Graves","year":"2020","journal-title":"World J Surg"},{"key":"10.1016\/j.eprac.2026.06.016_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.surg.2025.109707","article-title":"Surgery for normocalcemic hyperparathyroidism is safe and effective","volume":"189","author":"Frye","year":"2026","journal-title":"Surgery"},{"issue":"8","key":"10.1016\/j.eprac.2026.06.016_bib72","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1210\/jc.2013-1518","article-title":"Bone mineral density evolution after successful parathyroidectomy in patients with normocalcemic primary hyperparathyroidism","volume":"98","author":"Koumakis","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.eprac.2026.06.016_bib73","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.surg.2021.08.047","article-title":"What happens to the bone structure after normocalcemic primary hyperparathyroidism surgery?","volume":"171","author":"Osorio-Silla","year":"2022","journal-title":"Surgery"},{"issue":"1","key":"10.1016\/j.eprac.2026.06.016_bib74","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.surg.2022.05.042","article-title":"Phenotypes of primary hyperparathyroidism: does parathyroidectomy improve clinical outcomes for all?","volume":"173","author":"Armstrong","year":"2023","journal-title":"Surgery"},{"issue":"2","key":"10.1016\/j.eprac.2026.06.016_bib75","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00268-022-06756-x","article-title":"Parathyroidectomy for normocalcemic primary hyperparathyroidism is associated with improved bone mineral density regardless of postoperative parathyroid hormone levels","volume":"47","author":"Lui","year":"2023","journal-title":"World J Surg"},{"issue":"3","key":"10.1016\/j.eprac.2026.06.016_bib76","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00423-018-1659-0","article-title":"Is parathyroidectomy safe and effective in patients with normocalcemic primary hyperparathyroidism?","volume":"403","author":"Traini","year":"2018","journal-title":"Langenbecks Arch Surg"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26010529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26010529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T10:09:52Z","timestamp":1793959792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X26010529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":76,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1530891X26010529"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2026.06.016","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Normocalcemic Primary Hyperparathyroidism: An Evolving Understanding","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2026.06.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}